Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc. , shared Paolo Tarantino’s, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, post on X, adding:
“Iza-Bren is very effective (not only in TNBC), but its profile is also very chemo-like.
What’s the targeted contribution vs non-specific uptake? Iza-Bren half-life is ~1 day!
What’s the correlation with EGFR expression? HER3 expression? Co-expression of both EGFR and HER3?”
Quoting Paolo Tarantino’s post:
“Impressive results from a phase 3 trial of Iza-Bren (anti-HER3/EGFR TOPO1 ADC) vs chemo in pretreated mTNBC, with improvement in PFS and OS. High rate of hematologic toxicities, including 5% febrile neutropenia. Phase 3 ongoing to confirm these results in a global population.”
Paolo Tarantino: Phase III Iza-Bren Shows PFS and OS Benefit in Pre-Treated mTNBC
Other articles featuring Raffaele Colombo and Paolo Tarantino on OncoDaily.
